29 Jun 2026 Recon: FDA will review generic GLP-1; India floats faster licensing for some devices Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
25 Jun 2026 Recon: FDA grants breakthrough designation to gen AI radiology tools; Oncology paper retraction casts doubt on China research Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
23 Jun 2026 Recon: Pfizer’s experimental therapy falters in lung cancer study; European patient access to new drugs worsens Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
22 Jun 2026 Recon: AbbVie forges $10.9 billion deal with Apogee; US FDA changes tack on Regenxbio's rare disease gene therapy Recon
18 Jun 2026 Recon: Biogen to acquire RayThera for $1B; FDA approves first generic version Roche flu drug Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
16 Jun 2026 Recon: FDA approves Merck's Welireg-Keytruda combo for kidney cancer; FDA staff signal support for Moderna’s flu shot in older adults Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
15 Jun 2026 Recon: Neumora abandons depression drug after Phase 3 misses; FDA signs off on Colorado’s plan to import drugs from Canada Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
11 Jun 2026 Recon: MHRA approves Novo’s weight-loss pill; Some US employers look to cut GLP-1 coverage in 2027 Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
09 Jun 2026 Recon: GSK to buy Nuvalent for $10.6B; Pentagon labels WuXi AppTec as linked to Chinese military Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
08 Jun 2026 Recon: FDA expands use of Pfizer’s Hympavzi for children with hemophilia; J&J to acquire Firefly Bio for $1B Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
